Metabolism

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

Friday, June 5, 2020 - 1:00pm

We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.

Key Points: 
  • We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.
  • This important milestone marks Arcturus transition into a clinical stage biopharmaceutical company, said Steve Hughes, M.D., Chief Development Officer of Arcturus.
  • The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious, urea cycle disorder with a prevalence of approximately 10,000 worldwide.

First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)

Wednesday, June 3, 2020 - 11:33am

This is the first study to evaluate the NAD metabolome in human liver samples.

Key Points: 
  • This is the first study to evaluate the NAD metabolome in human liver samples.
  • This new study assessed the NAD metabolome in transplant and tissue resections from 72 patients with ArLD or four other conditions.
  • Analysis of liver tissue from the 43 ArLD patients showed marked depletion of NAD and its precursors.
  • Depressed NAD levels correlated with low markers of liver function, suggesting that liver NAD status is important for human health.

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules

Monday, May 18, 2020 - 5:33am

Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.

Key Points: 
  • Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.
  • The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product.
  • In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454

Tuesday, May 19, 2020 - 1:00pm

SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.

Key Points: 
  • SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.
  • "TP-1454 will be the first PKM2 activator to be tested in cancer patients, representing a novel mechanism that aims to target the underlying metabolics driving tumor growth and anti-cancer immune suppression.
  • We look forward to building our understanding of the potential role of PKM2 activation in the treatment of solid tumors."
  • TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, that will be evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.

Metabolic Partnering Deals Collection 2014-2020: Access to Over 950 Deal Records

Monday, May 18, 2020 - 4:45pm

This report provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Key Points: 
  • This report provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
  • Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities.
  • Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014.

Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials - ResearchAndMarkets.com

Monday, May 18, 2020 - 1:47pm

The "Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
  • Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014.
  • In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014.

Global Industrial Enzymes Industry (2020 to 2026) - Encapsulation to Enhance Shelf-Life Presents Lucrative Opportunities - ResearchAndMarkets.com

Tuesday, May 5, 2020 - 2:47pm

However, the growth of the industrial enzymes market is inhibited by factors, such as high adaptation costs involved for small-&-medium-sized enterprises.

Key Points: 
  • However, the growth of the industrial enzymes market is inhibited by factors, such as high adaptation costs involved for small-&-medium-sized enterprises.
  • In addition, the stringent regulatory framework for the use of industrial enzymes inhibits the growth of this market.
  • Proteases are essential enzymes for the digestion of protein and have become significant for use in the food & beverage industry.
  • Furthermore, the changing consumer preference in the food & beverage industry has contributed to the growth of the industrial enzymes market in this region.

Monash University Launches New App Category to Support Growing 'App'etite for ModifyHealth's Low-FODMAP Nationwide Meal Delivery Service.

Wednesday, April 29, 2020 - 2:20pm

"The Monash University FODMAP Diet app is the gold standard when it comes to helping patients understand the intricacies of the Low-FODMAP protocol and how different foods can impact their gut health.

Key Points: 
  • "The Monash University FODMAP Diet app is the gold standard when it comes to helping patients understand the intricacies of the Low-FODMAP protocol and how different foods can impact their gut health.
  • "We're incredibly excited to welcome ModifyHealth as the first company to lead this new category within our app."
  • "Monash University is the birthplace of the Low-FODMAP protocol and known internationally as leading experts in IBS research.
  • "We're honored to be the first prepared meal delivery service to earn Monash University's certification and are excited to see this category within their app.

Life Science Instrumentation Market Worth $79.9 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Tuesday, April 21, 2020 - 2:30pm

The Next-generation sequencing (NGS) segment is expected to register the highest growth over the forecast among the life science instrumentation technologies market over the forecast period.

Key Points: 
  • The Next-generation sequencing (NGS) segment is expected to register the highest growth over the forecast among the life science instrumentation technologies market over the forecast period.
  • The North American region accounted for the largest share of the life science instrumentation market in 2019.
  • The high adoption rate of novel technologies and the large number of life science research studies conducted in this region.
  • Moreover, stringent drug development regulations, increased funding for life science research activities, and the growing number of metabolomics research studies are some of the major factors driving the growth of the life science instrumentation sector in North America.

Life Science Instrumentation Market Worth $79.9 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Tuesday, April 21, 2020 - 2:30pm

The Next-generation sequencing (NGS) segment is expected to register the highest growth over the forecast among the life science instrumentation technologies market over the forecast period.

Key Points: 
  • The Next-generation sequencing (NGS) segment is expected to register the highest growth over the forecast among the life science instrumentation technologies market over the forecast period.
  • The North American region accounted for the largest share of the life science instrumentation market in 2019.
  • The high adoption rate of novel technologies and the large number of life science research studies conducted in this region.
  • Moreover, stringent drug development regulations, increased funding for life science research activities, and the growing number of metabolomics research studies are some of the major factors driving the growth of the life science instrumentation sector in North America.